Vitanova Biomedical

01/09/2026

I am excited to share the power of our Light Activated Intracellular Acidosis therapy to treat an aggressive plasma cell tumor in a cat.
www.vitanovabiomedical.com

11/27/2025

I’m thrilled to officially introduce Vitanova Biomedical and share our mission: transforming cancer care with next-generation light-activated therapies.
Our team is pioneering LUXVIVO, a novel cancer treatment proven to kill tumors while minimizing side effects. By leveraging light-activated intracellular mechanisms, we aim to provide safer, more effective options for both companion animals and, ultimately, human patients.
At Vitanova, our approach is scientifically rigorous and innovation-driven. We are currently advancing our pathway to gain FDA approval to treat melanoma in dogs, and are committed to building a foundation for a new era of precision oncology for all companion animals and humans.
This is just the beginning – stay tuned for updates on our journey, breakthroughs in therapy, and opportunities to collaborate. To learn more about us, please visit

Improving the lives of patients and companion animals with cancer and the professionals who care for them.

11/12/2025

We are excited to announce that we have been granted Minor Use/Major Species, or "MUMS" designation by the FDA Centers for Veterinary Medicine for developing our Light Activated Intracellular Acidosis therapy to treat hemangiosarcoma and osteosarcoma in dogs. To learn more, please visit www.vitanovabiomedical.com.